Non-intrusive Detection of Temporary Neurologic Impairment By Opioids

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 28, 2020

Primary Completion Date

April 11, 2022

Study Completion Date

April 11, 2022

Conditions
Healthy
Interventions
DRUG

Oxycodone

5 mg tablet

DRUG

Placebo

Oxycodone-matched placebo tablet

DEVICE

EyeLink 1000 Plus

Non-invasive video-based eye tracking system

DIAGNOSTIC_TEST

Oculo-Cognitive Addition test (OCAT)

Subject will have to look for numbers on a screen and add these numbers together. OCAT will be presented on a computer screen with attached eye tracking device at the bottom part.

DEVICE

VT3mini - Eye Tracking Technology for OEMs

Non-invasive eye-tracking device

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04223609 - Non-intrusive Detection of Temporary Neurologic Impairment By Opioids | Biotech Hunter | Biotech Hunter